Ultime notizie per Nvni Group (NASDAQ:NVNI) Azioni

Nvni Group

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

Nvni Group Ltd

News

onsemi Expands Collaboration With Schaeffler Through New Design Win Leveraging onsemi's Next-Gen EliteSiC Product Line Of Silicon Carbide MOSFETs

Good Morning Traders! 
Today&#8217;s economic calendar commences with the ECB&#8217;s Interest Rate decision at 8:15 AM ET, where rates are anticipated to remain unchanged for the first time in this cycle, potentially offering clues on future European monetary policy directions through accompanying statements or press conferences. Shortly after, at 8:30 AM ET, the weekly Initial and Continuing Jobless Claims will be published, providing essential updates on U.S. labor market conditions and unemployment trends that could sway sentiment regarding economic resilience.&nbsp;
Continuing at 9:45 AM ET, the Preliminary S&amp;P Global Manufacturing PMI, Services PMI, and Composite PMI for July will emerge, delivering early indicators of sector performance and overall business activity that often preview broader growth patterns. At 10:00 AM ET, June&#8217;s New Home Sales figures will shed light on housing market vitality, influenced by mortgage rates and buyer demand, while the Kansas City Fed Manufacturing Activity Index at 11:00 AM ET rounds out regional industrial insights.&nbsp;
Concluding at 1:00 PM ET, the Treasury&#8217;s 10-Year TIPS Auction may reflect investor inflation expectations through demand levels. Amid this substantial data flow and ongoing reactions to yesterday&#8217;s earnings from GOOGL and TSLA, prepare for notable market fluctuations, advocating for proactive monitoring and strategic adjustments. 
Now, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is presently trading near our important level of 634.72. Bulls are targeting an initial advance to 635.97. If momentum persists above 635.97, we anticipate buyers driving prices toward our next key support at 637.51. Should buyers confidently defend 637.51 throughout regular session trading, look for a continuation upward to 638.37, with our ultimate bullish target for the day sitting at 639.21.&nbsp;
If bulls lose their grip at 634.72, sellers will aim for downside momentum, initially challenging the 633.66 level. Continued bearish pressure will put the 632.37 mark at risk. Breaking this level decisively could see SPY quickly trading down toward the strong support at 630.63. If selling intensifies dramatically, bears might reach our lowest target for the session at 629.08.
Invesco QQQ Trust Series 1 (QQQ)
The QQQ is currently trading near our pivotal level of 565.19. Bulls must firmly establish price action above this mark, subsequently securing 567.12 as reliable intraday support. Persistent bullish sentiment should then encourage further upside momentum, targeting the next resistance at 569.60. If today&#8217;s buying is robust, anticipate a stretch toward 572.98, with our top bullish objective for the QQQ standing at 576.28.&nbsp;
Should QQQ fail to hold 565.19 convincingly during market hours, bears will seize control and push downward aggressively, first testing the 563.44 area. If weakness persists, expect a deeper selloff toward 562.30. Continued bearish dominance could trigger further downside pressure toward the support at 560.58. A breach here opens the door to our lowest bearish target of the day at 559.57.
Apple Inc. (AAPL)
Apple is trading near our crucial price level of 213.75. Bulls should aim to maintain this support, driving the stock upward initially toward 215.06. Sustained buying could elevate Apple to the next upside hurdle at 216.38. If bullish participants decisively dominate today&#8217;s trading, our high-end bullish target of 218.01 becomes attainable.&nbsp;
If buyers fail to defend the critical level at 213.75, bearish sellers will quickly target 212.75 as their first destination. Continuation of selling momentum would bring Apple down to the next support zone at 211.87. A breakdown of that level might induce additional selling toward 211.12, with further weakness potentially reaching our lower bear target at 210.49.
Microsoft Corp. (MSFT)
Microsoft is currently trading near our highlighted level of 505.87. Bulls will first need to secure the area above 505.57, setting the stage for a move upward toward 507.77, which would then act as an intraday support. Holding firmly above 507.77 would position Microsoft for a bullish run toward 509.64, with sustained buyer participation likely pushing prices to our daily bullish target of 512.08.&nbsp;
If 505.87 is not maintained, expect bears to swiftly challenge the 504.70 mark. Breaking below this support will encourage additional downside pressure, targeting 503.15. Should selling intensify, the next bearish objective becomes 501.63, ultimately opening a path toward our lowest bearish target for the session at 500.26.
NVIDIA Corporation (NVDA)
NVIDIA is currently trading around our critical level of 172.77. Bulls must push the price higher initially to reclaim and firmly establish support at 173.81. Continued upward momentum would then open a pathway to the next resistance point at 175.18. Strong buying throughout the day could drive NVIDIA further upward toward 176.52, with our top bullish target today placed at 178.18.&nbsp;
If NVIDIA cannot hold above 172.77, expect bearish sellers to target a move lower initially toward 170.57. A breakdown here with notable selling volume could rapidly take prices down to 169.06. Further weakening could see bears testing 167.75, and continued downside momentum might ultimately push NVIDIA toward our daily bearish objective at 166.76.
Alphabet Inc Class A (GOOGL)
Alphabet is presently trading close to our significant level of 197.50. Bulls will first aim to firmly secure this area as intraday support, targeting a push higher toward resistance at 198.55. Strong bullish activity might then extend this rally to reach today&#8217;s ultimate bullish target of 200.42.&nbsp;
If buyers are unable to protect 197.50, sellers will likely take control and aggressively test support lower at 196.39. If bearish sentiment intensifies, expect the auction to continue downward toward 195.28. Under heavy selling pressure, Alphabet could fall toward our low-end bearish objective of 193.55.
Meta Platforms Inc (META)
Meta is currently trading near our key level of 718.80. Bulls will look to establish firm price strength above 721.51, setting up the opportunity for further advances toward 723.46. Continued bullish conviction should then lift Meta toward the next resistance level at 726.10, with potential for buyers to drive price action toward our bullish target at 728.75.&nbsp;
If Meta fails to maintain support at 718.80, sellers will immediately target a decline to the support level at 714.89. Continued bearish activity would encourage a further drop toward 712.43. Should this area fail to hold, increased selling might accelerate the move down toward our lowest bearish target of the session at 710.43.
Tesla Inc. (TSLA)
Tesla is currently trading around our significant price level of 313.05. Bulls should first target a move upward to 315.33, with continued buying momentum potentially lifting prices to the next resistance at 319.01. If market sentiment is strongly bullish today, Tesla may push higher toward 324.94, with our maximum bullish objective sitting at 327.19.&nbsp;
If the support level at 313.05 is compromised, anticipate sellers moving swiftly to test lower prices around 311.21. Additional bearish pressure would likely bring Tesla down further to 309.37. Failure at this level with intensified selling could prompt further downside to our daily bearish target of 307.98.
Good luck and trade safely!
&#x2A;&#x2A;.
Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content or accuracy.
&#x2A;&#x2A;

Equities

Technicals

Opinion

Signals

Trading Ideas

How To Trade SPY, Top Tech Stocks Today Using Technical Analysis

The shares of Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) climbed 3.87% in Thursday pre-market after its Q2 financial results surpassed analyst expectations. The company attributed the strong performance to a growing demand for cloud services. 
What Happened: On Wednesday, Alphabet announced that its Q2 revenue stood at $96.43 billion, outperforming the projected $93.72 billion. The company&#8217;s EPS was $2.31, surpassing the <a href="https://www.benzinga.com/markets/earnings/25/07/46587283/alphabet-q2-earnings-revenue-eps-beat-estimates-google-parent-raises-capex-outlook-due-to-strong-and-growing-cloud-demand">anticipated </a>$2.16. This marks the tenth consecutive quarter of Alphabet exceeding analyst expectations.
Alphabet&#8217;s EPS rose by 22% year-over-year, with total revenue increasing by 14% year-over-year, driven by strong performance across the business. The company&#8217;s cash, cash equivalents, and marketable securities totaled approximately $95.15 billion at the end of the quarter.
Alphabet&#8217;s CEO, Sundar Pichai, highlighted the company&#8217;s leadership in AI and its positive impact on all business areas. He also noted strong performance in YouTube and subscription offerings, and significant growth in cloud revenues, backlog, and profitability.
Due to the &#8220;strong and growing demand&#8221; for cloud products and services, Alphabet has raised its CapEx outlook for 2025 to roughly $85 billion.
SEE ALSO:&nbsp;<a href="https://benzinga.com/real-estate/25/07/46564953/kevin-oleary-calls-trumps-no-tax-on-home-sales-plan-common-sense-shark-says-families-can-grow-without" target="_blank" rel="noreferrer noopener">Kevin O&#8217;Leary Calls Trump&#8217;s No Tax On Home Sales Plan &#8216;Common Sense&#8217;: Shark Says, &#8216;Families Can Grow Without Getting Punished&#8217;</a>
Why It Matters: Despite Alphabet&#8217;s <a href="https://www.benzinga.com/markets/tech/25/07/46592273/gene-munster-says-ai-risk-is-still-on-the-table-for-google-despite-blowout-q2-earnings-but-admits-search-was-strong-for-alphabet-investors-will-likely-co">impressive </a>Q2 earnings, the company&#8217;s future is still tied to its ability to navigate the AI revolution. Tech analyst Gene Munster noted that Alphabet&#8217;s future success hinges on its AI strategy.
Meanwhile, Alphabet&#8217;s CEO Sundar Pichai <a href="https://www.benzinga.com/markets/tech/25/07/46593735/google-ceo-sundar-pichai-shrugs-off-headling-grabbing-exits-amid-talent-war-hype-we-are-doing-very-well">dismissed </a>concerns about an AI talent exodus, stating that the company remains competitive in attracting and retaining top talent. This is crucial as Alphabet&#8217;s AI leadership has a significant impact on all its business areas, as highlighted in the Q2 earnings call.
According to Benzinga Edge Stock Rankings, Alphabet has a growth score of 87.24% and a momentum rating of 47.38%. Click <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here </a>to see how it compares to other leading tech companies.
READ MORE:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46538265/google-is-at-a-crossroads-t-rowe-price-portfolio-manager-flags-chatgpt-as-key-disruption-risk-as-search-giant-transitions-from-librarian-to-expert">&#8216;Google Is At A Crossroads&#8217;: T. Rowe Price Portfolio Manager Flags ChatGPT As Key Disruption Risk—As Search Giant Transitions From &#8216;Librarian&#8217; To &#8216;Expert&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

GOOG

GOOGL

Alphabet Stock Climbs Nearly 4% In Thursday Pre-Market: What's Going On?

Investor sentiment around several major stocks got a boost this week thanks to upbeat commentary from Jim Cramer <a href="https://www.benzinga.com/topic/jim-cramer">and fresh analyst support</a>.
On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Cramer praised both Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) and CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>).
&#8220;Marvin Ellison [CEO of Lowe&#8217;s] is hitting the ball,&#8221; Cramer added <a href="https://www.benzinga.com/quote/LOW/analyst-ratings">with a buy recommendation</a>. &#8220;He's doing his best.&#8221;
Supporting his view, Guggenheim analyst Steven Forbes, on July 22, reiterated Lowe&#8217;s Companies with a Buy and maintained a $300 price target.
When asked about CrowdStrike, he said, &#8220;Take out your cost basis, and then you're going to let the rest run. And I'll see you at $1000.&#8221;
Macquarie analyst Steve Koenig, on July 17, initiated coverage on CrowdStrike with a Neutral rating and announced a price target of $465.
&#8220;We're still on the verge of finding out what this Seagen acquisition does,&#8221; Cramer said when asked about Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>). &#8220;Let's give Dr. Bourla [CEO of Pfizer] two more quarters.&#8221;
As per the recent news, Bristol Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) and Pfizer alliance, on July 17, announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance's patient resource, Eliquis 360 Support, on Thursday. Eliquis is a blood-thinning medication that reduces blood clotting and prevents strokes.
Price Action:
<ul class="wp-block-list">
<li>Pfizer shares gained 0.9% to settle at $25.36 on Wednesday.</li>
<li>CrowdStrike shares fell 2.1% to close at $461.52.</li>
<li>Lowe's shares gained 1.3% to settle at $228.61 on Wednesday.</li>
</ul>
Read Next:<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46570034/jim-cramer-likes-stocks-yield-not-fundamentals"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46570034/jim-cramer-likes-stocks-yield-not-fundamentals">Jim Cramer Loves &#8216;That Yield&#8217; But Passes On This Stock: &#8216;Fundamentals Are Hurting&#8217;</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

CRWD

Jim Cramer Praises Lowe's CEO, As For CrowdStrike: 'I'll See You At $1000'

Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026
If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.atarabio.com%2F&amp;esheet=54295784&amp;newsitemid=20250724273588&amp;lan=en-US&amp;anchor=Atara+Biotherapeutics%2C+Inc.&amp;index=1&amp;md5=7ea13e148a3f6cf4c27aae0f231c3376">Atara Biotherapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for tabelecleucel (tab-cel&#xAE;) indicated as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. There are no FDA approved therapies in this treatment setting.
The BLA has been granted Priority Review with a Class 2 Resubmission Prescription Drug User Fee Act (PDUFA) target action date of January 10, 2026.

ATRA

Atara Biotherapeutics Says FDA Accepts Filing Of BLA For Tabelecleucel Indicated As Monotherapy For Treatment Of Patients With EBV+ PTLD Who Have Received At Least One Prior Therapy

Biotech

General

ADTX

Aditxt's Subsidiary Pearsanta Announces It Has Received Invitation To Submit Full Proposal For U.S. Department Of Defense Pilot Award For The Development of Its Mitomic Ovarian Test

First prospective, multi-center trial to examine how dd-cfDNA can be used in post-rejection patient management
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54295747&amp;newsitemid=20250724340120&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=4e4f10aedaaae8fc3baf68a4a94e36fc">Natera, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a global leader in cell-free DNA testing and precision medicine, today announced that the American Journal of Transplantation published findings from the PEDAL study. PEDAL is the first prospective multi-center trial evaluating longitudinal trends of donor-derived cell-free DNA (dd-cfDNA) to determine the prognostic ability of Prospera in assessing outcomes following kidney transplant rejection.
PEDAL enrolled 488 kidney transplant recipients from 28 participating U.S. and international transplant centers over 4 years. 66 patients with biopsy-proven acute rejection (BPAR) were longitudinally tested with Prospera in the immediate eight-weeks following BPAR and clinical outcomes were recorded at 12-months. Results from the study demonstrated that Prospera dd-cfDNA trends post-rejection are strongly associated with and prognostic of one-year outcomes.
Key findings included:
<ul>
<li>The odds of experiencing positive outcomes after 1 year were 60x higher among patients with low/decreasing Prospera trends. These patients were also 13x more likely to have resolving kidney dysfunction.</li>
<li>Conversely, 97.5% (40/41) of cases with sustained elevated/high Prospera trends experienced negative clinical outcomes.</li>
<li>Prospera trends were statistically associated with outcomes, suggesting dd-cfDNA may help physicians manage patients post-BPAR.</li>
</ul>

NTRA

Natera Says American Journal Of Transplantation Publishes Findings From PEDAL Study; Study Shows Monitoring With Prospera Kidney Provides Accurate Prognosis Of Long-Term Clinical Outcomes Following Rejection

Macro Economic Events

Global

Economics

ECB Leaves Deposit Rate Unchanged At 2.0%, Refi Rate Unchanged At 2.15%

Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026
If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.atarabio.com%2F&amp;esheet=54295784&amp;newsitemid=20250724273588&amp;lan=en-US&amp;anchor=Atara+Biotherapeutics%2C+Inc.&amp;index=1&amp;md5=7ea13e148a3f6cf4c27aae0f231c3376">Atara Biotherapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for tabelecleucel (tab-cel&#xAE;) indicated as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. There are no FDA approved therapies in this treatment setting.
The BLA has been granted Priority Review with a Class 2 Resubmission Prescription Drug User Fee Act (PDUFA) target action date of January 10, 2026.
"The acceptance of the tab-cel resubmission moves us one step closer towards making this first-of-its-kind treatment available to patients in the U.S.," said Cokey Nguyen, President and Chief Executive Officer of Atara. "We continue to work closely with the Pierre Fabre Pharmaceuticals team to help prepare for the potential launch in the U.S."
Tab-cel is an allogeneic, EBV-specific T-cell immunotherapy designed to target and eliminate EBV-infected cells. The BLA is supported by pivotal and supportive data covering more than 430 patients treated with tab-cel across multiple life-threatening diseases, including the latest pivotal ALLELE study data that demonstrated a statistically significant 48.8% Objective Response Rate (ORR) (p&lt;0.0001) and favorable safety profile consistent with previous analyses.

Atara's Biologics Announces Its License Application Was Granted Priority Review For Tabelecleucel An Allogenic, EBV‑Specific T‑Cell Therapy For Treating EBV⁺ Post-Transplant Lymphoproliferative Disease Has Been Accepted By The U.S. FDA

BIVI

BioVie Highlights Presentation Titled 'Bezisterim Decreases Biological Age Acceleration in Alzheimer's Disease' From Jul. 14-15

ILAG

Intelligent Living Granted Additional 180 Days By NASDAQ To Regain Compliance With Minimum Bid Price Rule

Tucker Carlson's latest podcast featuring Trevor Milton, the former Nikola Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NKLAQ#OTC">NKLAQ</a>) CEO pardoned by President Donald Trump in March 2025, has ignited a firestorm of criticism.
What Happened: Billionaire investor Bill Ackman led the charge, slamming Carlson for platforming Milton, whom he labeled a "convicted corporate stock market fraudster," while endorsing the <a href="https://www.benzinga.com/news/management/25/01/43017547/hindenburg-research-is-closing-up-shop-we-shook-some-empires-that-we-felt-needed-shaking">now-closed firm</a> Hindenburg Research founder Nate Anderson's rebuttal to Carlson's podcast.
The controversy erupted after Carlson's July 23 interview, where Milton alleged that a Wall Street and FBI conspiracy destroyed his company over its hydrogen truck ambitions.
Quoting Anderson's detailed takedown, Ackman said, &#8220;@TuckerCarlson is now platforming a convicted corporate stock market fraudster.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">.<a href="https://twitter.com/TuckerCarlson?ref_src=twsrc%5Etfw">@TuckerCarlson</a> is now platforming a convicted corporate stock market fraudster. <a href="https://t.co/pHsQS0nO8r">https://t.co/pHsQS0nO8r</a>
&mdash; Bill Ackman (@BillAckman) <a href="https://twitter.com/BillAckman/status/1948297192822677824?ref_src=twsrc%5Etfw">July 24, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Anderson defended Hindenburg's 2020 report that exposed Milton's fraudulent claims, leading to his 2023 conviction and a four-year sentence—later commuted after a $900,000 Trump donation.
He highlighted <a href="https://www.benzinga.com/markets/equities/25/01/43018900/from-adani-to-nikola-how-hindenburg-research-reshaped-short-selling-before-its-final-bow">several inaccuracies</a> in Milton&#8217;s interview, such as the false claim that Hindenburg paid for inside information and exaggerated profit figures from their short position on Nikola.
Anderson also points out Milton&#8217;s omission of significant details, like his <a href="https://www.benzinga.com/markets/equities/25/03/44528332/trump-pardons-nikola-founder-trevor-milton-short-seller-jim-chanos-reacts-please-tell-me-this-is-a-hoax">substantial donation to Trump</a> before the 2024 election and allegations of sexual assault, which contextually undermine Milton&#8217;s narrative of victimization.
"Trevor Milton is a convicted fraudster held criminally responsible for the incineration of hundreds of millions of dollars," Anderson asserted, dismissing Milton's narrative as "bizarre and fantastical."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I am Nate Anderson, the founder of Hindenburg Research referenced repeatedly in this bizarre and fantastical interview. During my career, I helped expose numerous financial scams, including over a dozen Ponzi schemes and numerous instances of public companies lying to and…
&mdash; Nate Anderson (@NateHindenburg) <a href="https://twitter.com/NateHindenburg/status/1948187246495985987?ref_src=twsrc%5Etfw">July 24, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46571050/ripple-circle-push-for-fed-access-as-5-7-trillion-stablecoin-surge-fuels-ambitions-to-replace-swift-says-industry-observer">Ripple, Circle Push For Fed Access As $5.7 Trillion Stablecoin Surge Fuels Ambitions To Replace SWIFT, Says Industry Observer</a>
Why It Matters: Carlson's portrayal of short-sellers like Hindenburg as villains, suggesting their practices should be criminalized, drew ire. Anderson countered, "Short sellers play a critical role in the functioning of healthy markets," urging Carlson to "vet the people you welcome."
Ackman's stance, given <a href="https://www.benzinga.com/government/24/10/41495497/bill-ackman-dealmaker-donald-trump-is-key-to-avoiding-world-war-3">his Trump support</a>, adds intrigue; however, Anderson&#8217;s response underscores the importance of short-selling in financial markets, likening it to investigative journalism.
Anderson&#8217;s defense of Hindenburg&#8217;s work is supported by the <a href="https://hindenburgresearch.com/">firm&#8217;s track record</a>, which includes exposing numerous frauds and leading to regulatory actions, as detailed on their website, reinforcing the credibility of their methods and findings.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">How Wall Street short sellers worked with the media and federal prosecutors to destroy Trevor Milton's company and put him in jail for life. This is a shocking story. (0:00) Introduction (0:31) The Origins of Milton's Hydrogen Truck Company Nikola (4:17) What Is a Hydrogen… <a href="https://t.co/N6iwiWMsd6">pic.twitter.com/N6iwiWMsd6</a>
&mdash; Tucker Carlson (@TuckerCarlson) <a href="https://twitter.com/TuckerCarlson/status/1948065573604343978?ref_src=twsrc%5Etfw">July 23, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Price Action: The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and&nbsp;Invesco QQQ Trust ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were slightly higher in premarket on Thursday. The SPY was up 0.041% at $634.47, while the QQQ advanced 0.27% to $565.34, according to&nbsp;<a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>&nbsp;data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46513468/bitcoin-miner-iren-could-surge-1572-as-sotp-valuation-pegs-300-target-hedge-fund-manager-eric-jackson-says-were-cooking-with-gas" target="_blank" rel="noreferrer noopener">Bitcoin Miner IREN Could Surge 1,572% As SOTP Valuation Pegs $300 Target — Hedge Fund Manager Eric Jackson Says, ‘We're Cooking With Gas'</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock/Maxim Elramsisy

Short Sellers

NKLAQ

Tucker Carlson's Milton Interview Sparks Outrage: Bill Ackman Backs Hindenburg Founder Against Former Nikola CEO, Calls Him 'Convicted Corporate Stock Market Fraudster'

Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) will release earnings results for the second quarter before the opening <a href="https://www.benzinga.com/quote/PSX/earnings">bell on Friday, July 25</a>.
Analysts expect the Houston-based company to report quarterly earnings at $1.71 per share, down from $2.31 per share in the year-ago period. Phillips 66 projects to report quarterly revenue at $32.32 billion. Compare that to $38.91 billion the previous year, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Tuesday, Piper Sandler analyst Ryan Todd maintained a Neutral rating for Phillips 66 and lowered the price target from $148 to $147.
With the recent buzz around Phillips 66, some investors may be eyeing potential gains from the company's dividends. Currently, Phillips 66 offers an annual dividend yield of 3.75% ($4.80 a year). That&#8217;s a quarterly dividend amount of $1.20 per share.
To earn $500 monthly from Phillips 66, start by setting a yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Phillips 66's $4.80 dividend: $6,000 / $4.80 = 1,250 shares.
So, an investor would need to own approximately $159,813 worth of Phillips 66, or 1,250 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $4.80 = 250 shares, or $31,963 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
PSX Price Action: Shares of Phillips 66 rose by 1.3% to close at $127.85 on Wednesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46570034/jim-cramer-likes-stocks-yield-not-fundamentals">Jim Cramer Loves &#8216;That Yield&#8217; But Passes On This Stock: &#8216;Fundamentals Are Hurting&#8217;</a></li>
</ul>
Image: Shutterstock

Earnings

Dividends

How To Earn $500 A Month From Phillips 66 Stock Ahead Of Q2 Earnings

The new plant can produce millions of single-serve coffee cups daily while bolstering the local economy by creating skilled manufacturing, quality assurance and logistics jobs.
The opening marks Westrock Coffee's second new production factory in the past year, establishing Arkansas as a leading U.S. coffee and beverage manufacturing hub.
CONWAY, Ark., July 24, 2025 /PRNewswire/ --&nbsp;Today, Westrock Coffee Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEST#NASDAQ">WEST</a>) ("Westrock Coffee" or the "Company"), North America's top manufacturer of private label coffee and tea, announces the expansion of its U.S. operations with a new manufacturing facility in Conway, Arkansas. The new facility is designed to help meet rising demand from existing and new global customers, including some of the largest retail and coffee brands in North America.

WEST

Westrock Coffee Expands U.S. Operations With New Manufacturing Facility In Conway, Arkansas

Major altcoins led by Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and Ripple&#8216;s XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) posted sharp declines on Thursday, reversing gains from a strong rally earlier this month.
What Happened: The broader cryptocurrency market experienced a notable selloff, with experts pointing to both overheated momentum and emerging signs of a corrective phase, even as structural fundamentals continue to strengthen.
According to data, Ethereum dropped 2%, while XRP fell by over 10%, leading losses among large-cap tokens. 
Other altcoins including BNB (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>), Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>), Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), and Tron (CRYPTO: TRON) also registered losses exceeding 4%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), in contrast, edged slightly higher, gaining 0.26% and maintaining relative stability during the downturn.
What Experts Are Saying: In a note sent to Benzinga, James Harris, CEO of institutional crypto firm Tesseract, said the market's recent surge to a $4 trillion total market cap was driven by a "powerful trifecta" of supportive forces, but he cautioned that these tailwinds come with their own risks.
"The rally has been underpinned by structural regulatory wins, improving macro conditions, and growing corporate treasury involvement," Harris explained. 
He noted that new U.S. legislation such as the GENIUS Act and progress on the CLARITY bill have triggered a sharp turnaround in institutional sentiment.
Also Read: <a href="https://www.benzinga.com/news/25/07/46581609/xrp-gets-its-own-treasury-company-look-whos-building-a-20-million-xrp-reserve">XRP Gets Its Own Treasury Company: Look Who&#8217;s Building A $20 Million XRP Reserve</a>
"Bitcoin jumped 10–15% after the legislation moved forward, and altcoins like ETH outpaced that," he said.
Harris also cited improving inflation data and expectations for interest rate cuts as key macroeconomic drivers behind the current risk-on sentiment. 
"As central banks around the world begin to shift toward easing, capital is flowing into assets like crypto that sit higher on the risk curve," he said.
Beyond the macro and regulatory backdrop, Harris pointed to a growing trend of public companies treating digital assets as treasury reserves. 
"Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) added over 20,000 BTC this year alone, and others are following," he noted. "We're seeing listed firms buying ETH, SOL, and even making those moves public — a self-reinforcing loop."
However, that same bullish setup could quickly unravel, Harris warned. "While momentum is strong, these forces can reverse quickly. Disciplined risk management remains essential."
Alex Kuptsikevich, Chief Market Analyst at FxPro, offered a more near-term technical outlook. 
"Altcoins, which had been fueling the rally, have sold off aggressively. Nearly half of the top 100 altcoins are posting double-digit losses," he said.
He also observed a narrowing range in Bitcoin's price movement:
"BTC's stability is critical. If it drops to $111,000, it would complete a textbook corrective pattern," Kuptsikevich added, warning that continued weakness could intensify bearish sentiment across the entire crypto market.
Despite recent ETF outflows in Bitcoin, Kuptsikevich noted that Ethereum continues to attract fresh capital into funds, highlighting diverging investor sentiment between the two largest assets.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46579590/altcoin-speculation-surges-is-crypto-headed-for-a-leverage-fueled-meltdown">Altcoin Speculation Surges: Is Crypto Headed For A Leverage-Fueled Meltdown?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$BNB

$BTC

$DOGE

$ETH

$SOL

$XRP

MSTR

Ethereum, XRP Sink While Bitcoin Holds: What's Going On With Altcoins?

Barclays analyst Andrew Mok maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and lowers the price target from $215 to $208.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Tenet Healthcare, Lowers Price Target to $208

Barclays analyst Raimo Lenschow maintains ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) with a Overweight and raises the price target from $1200 to $1210.

Barclays Maintains Overweight on ServiceNow, Raises Price Target to $1210

SUUN

SolarBank Announces Name Change To PowerBank Corporation

Barclays analyst Alex Scott maintains RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) with a Equal-Weight and raises the price target from $256 to $273.

Barclays Maintains Equal-Weight on RenaissanceRe Holdings, Raises Price Target to $273

<ul>
<li>Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5525 alone or in combination with pembrolizumab in a variety of EGFR-expressing solid tumors such as NSCLC, CRC, HNSCC and cSCC</li>
<li>VIR-5525, the Company's third dual-masked T-cell engager leveraging the PRO-XTEN&#x2122; technology, is designed to expand the therapeutic index by selectively activating in the tumor microenvironment</li>
<li>Dose escalation continues for Phase 1 studies of PRO-XTEN&#x2122; dual-masked TCEs VIR-5818 (HER2) and VIR-5500 (PSMA), with compelling early clinical response signals and promising safety profiles</li>
</ul>
Vir Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) today announced that the first patient has been dosed in the Company's Phase 1 clinical trial evaluating VIR-5525, an investigational dual-masked T-cell engager (TCE) targeting EGFR (epidermal growth factor receptor). VIR-5525 will be evaluated for the treatment of a variety of EGFR-expressing solid tumors in areas of high unmet need such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), and cutaneous squamous cell carcinoma (cSCC).
The Phase 1 clinical trial (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06960395%3FfirstPost%3D2012-03-03_&amp;esheet=54295627&amp;newsitemid=20250724060737&amp;lan=en-US&amp;anchor=NCT06960395&amp;index=1&amp;md5=21c12fa77bc5c8ec6b0e7c4ea5d998c7">NCT06960395</a>) is a first-in-human open-label, non-randomized study designed to assess the safety, pharmacokinetics, and preliminary anti-tumor activity of VIR-5525 as a monotherapy and in combination with pembrolizumab. VIR-5525 is Vir Biotechnology's third dual-masked TCE in clinical trials. It incorporates the Company's clinically validated in-licensed PRO-XTEN&#x2122; masking technology, which is designed to enable the selective activation of the TCEs in the tumor microenvironment, mitigating damage to healthy cells and reducing toxicity.
EGFR is a clinically validated target known to play a key role in cancer.1 Although EGFR-targeting therapies are available, they often face limitations due to the development of resistance mechanisms and high toxicities associated with treatment.

Vir Biotechnology Announces First Patient Dosed In Phase 1 Clinical Trial Evaluating VIR-5525, Investigational Dual-Masked T-Cell Engager Targeting EGFR

Press Releases

AI Co's: ARBB, GEVI, CYCU, CBDW + More Driving Innovation Across Industries

Nuvini Group Announces Term Sheet for the Acquisition of B2B SaaS Platform Munddi

Nvni Group Receives Non-Compliance Notice from Nasdaq

Nvni Group Limited Reports Record 2024 Financial Results

May 2025 Letter to Shareholders of Nvni Group Limited

Nuvini Group Completes Acquisition of B2B SaaS Platform Munddi

Nuvini Group Announces Participation in the Sidoti Micro-Cap Investor Conference

Events

Sidoti Events, LLC's Virtual May Micro-Cap Conference

June 2025 Letter to Shareholders of Nvni Group Limited

Nuvini Hosts Inaugural NuviniAI Day: Culmination of Strategic AI Initiative at Oracle São Paulo

Comments

Nvni Group

Notizie

Ultime notizie per Nvni Group (NASDAQ:NVNI) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO